Form 483 Hits the SweetSpot for Alleged Follow-up Issues

By egp dave March 3, 2016 The GMP Letter No Comments

The FDA cited a diabetes device data firm for alleged procedural failings in a recent FDA Form 483.
Source: The GMP Letter